Filed under: Investing
The CEOs of both Bristol-Myers Squibb and Teva Pharmaceutical Industries have indicated that they're looking to make deals at the moment. In this video, Motley Fool health-care analyst David Williamson looks at both companies and how successful some of their recent mergers and acquisitions were. He also examines several possible takeover candidates and discusses just how likely each might be for an acquisition by BMY or TEVA. Finally, David tells investors which of the two he sees as stronger at the moment, and how this pricey bull market may affect the companies' decisions.
What's the best way to play the biotech sector?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article 2014 Trend Alert: Health-Care M&A originally appeared on Fool.com.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
Read | Permalink | Email this | Linking Blogs | Comments